Human Growth Hormone Agent Humatrope Now Available for Treatment of Adult Growth Hormone Deficiency.Tokyo, Japan, Apr 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Eli Lilly Eli Lilly can refer to:
Now Humatrope is indicated for patients with severe adult growth hormone deficiency growth hormone deficiency Hypopituitarism Endocrinology A condition which affects 1:4000 children; ♂:♀, 3-4:1 Etiology 70% of GHD is idiopathic and attributed to a prenatal insult, possibly due to hypothalamic dysfunction, given that GHD children . The company aims to contribute to reducing the risk of cardiovascular diseases and improving the quality of life of those patients. Initially commercialized by US Eli Lilly in 1987, Humatrope is currently approved for the treatment of adult growth hormone deficiency in more than 60 countries worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion